Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.398 DKK -0.57%
Market Cap: 635.6m DKK

Operating Margin
Bioporto A/S

-265.7%
Current
-231%
Average
-4.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-265.7%
=
Operating Profit
-91.5m
/
Revenue
34.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DK
Bioporto A/S
CSE:BIOPOR
600.7m DKK
-266%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
327.6B USD
30%
US
Amgen Inc
NASDAQ:AMGN
155.7B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
134.5B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
116.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.6B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.7B USD
-5%

Bioporto A/S
Glance View

Market Cap
600.7m DKK
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

BIOPOR Intrinsic Value
1.079 DKK
Overvaluation 23%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-265.7%
=
Operating Profit
-91.5m
/
Revenue
34.4m
What is the Operating Margin of Bioporto A/S?

Based on Bioporto A/S's most recent financial statements, the company has Operating Margin of -265.7%.

Back to Top